Jacob Ma-Weaver Joins ARCA biopharma Board of Directors
June 21, 2022 16:05 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob...
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
May 05, 2022 16:15 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In...
ARCA biopharma Announces First Quarter 2022 Financial Results
May 02, 2022 16:15 ET
|
ARCA biopharma, Inc.
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE...
ARCA biopharma Establishes Special Committee of the Board of Directors
April 18, 2022 16:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial
March 31, 2022 16:15 ET
|
ARCA biopharma, Inc.
For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in D-dimer levels of 16.8% versus 11.2% for...
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update
March 14, 2022 16:15 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2
January 04, 2022 08:30 ET
|
ARCA biopharma, Inc.
Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important...
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
September 16, 2021 08:30 ET
|
ARCA biopharma, Inc.
First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in...
ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th
August 16, 2021 08:05 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2
August 09, 2021 08:00 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...